Search

Krystal Biotech Inc

Fermé

SecteurSoins de santé

356 -1.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

351.1

Max

362.86

Chiffres clés

By Trading Economics

Revenu

-1.2M

55M

Ventes

2.9M

119M

P/E

Moyenne du Secteur

43.421

57.366

BPA

1.79

Marge bénéficiaire

45.938

Employés

295

EBITDA

2.9M

66M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.05% upside

Dividendes

By Acuity

Prochains Résultats

2 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-257M

10B

Ouverture précédente

357.02

Clôture précédente

356

Sentiment de l'Actualité

By Acuity

14%

86%

26 / 340 Classement par Healthcare

Krystal Biotech Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 20:07 UTC

Krystal Biotech Inc shares are higher today, benefiting from easing Treasury yields and strong momentum, despite no specific company news driving the move.

24 août 2026, 19:16 UTC

Krystal Biotech Inc's shares are lower today, continuing a decline since Friday. Market focus remains on upcoming economic events amid inflation concerns.

21 août 2026, 21:01 UTC

Krystal Biotech shares are lower in after-market trading, reflecting a modest decline since Friday's close amid limited price fluctuations.

20 août 2026, 21:01 UTC

Krystal Biotech Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average without any specific news to explain the rise.

19 août 2026, 20:02 UTC

Correlated Moves

Shares rise amid positive momentum in biotechnology sector.

14 août 2026, 19:46 UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

13 août 2026, 19:46 UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

12 août 2026, 20:52 UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

11 août 2026, 21:01 UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

7 août 2026, 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6 août 2026, 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5 août 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4 août 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 août 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 juil. 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 juil. 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 juil. 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 juil. 2026, 20:03 UTC

Event
Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27 juil. 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24 juil. 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23 juil. 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22 juil. 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21 juil. 2026, 18:36 UTC

News
Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 juil. 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Comparaison

Variation de prix

Krystal Biotech Inc prévision

Objectif de Prix

By TipRanks

13.05% hausse

Prévisions sur 12 Mois

Moyen 402.67 USD  13.05%

Haut 474 USD

Bas 361 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

26 / 340Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat